đź“… SAVE THE DATE: July 14th – 16th, 2025 | Boston, MA
LINKÖPING, Sweden, July 3, 2025 – We are absolutely thrilled to join the 3rd Annual Obesity and Weight Loss Drug Development Summit as the 2025 Lead Partner! Join our CEO, Dr. Olof Dahlqvist Leinhard, as he discusses how transformative MRI-based body composition methods and AMRA’s unique biomarkers are redefining obesity drug trials:
🔬 “MRI-based Body Composition Reimagined: Building a New Foundation for Treatment Differentiation Beyond Weight Loss”
👨🏻‍🔬 Olof Dahlqvist Leinhard, PhD
đź—“ July 15th, 9:00am
The Obesity and Weight Loss Drug Development Summit, entering its third year, gathers the leading pharma, biotech, clinical, and academic thought partners to chart the next wave of obesity therapeutics—from navigating new guidelines to advancing personalized, muscle-preserving and side-effect-sparing treatment strategies.
As the obesity treatment landscape has evolved significantly over the past few years with the advent of GLP-1-based therapies, AMRA has been involved in many high-profile studies that evaluate the effects of anti-obesity medications on fat distribution and muscle composition. AMRA’s novel body fat and muscle volume z-score biomarkers uncover and help quantify these deeper-than-surface-level changes in body composition, and deepening insights within obesity treatment differentiation.
Powered by AMRAⓇ Researcher, the body fat and muscle volume z-score biomarkers provide reproducible and reliable measures of fat distribution and muscle composition, determining how far each participant deviates from the expected fat or muscle volume for someone with their sex and body mass index.
This new, sex-, height-, weight-, and BMI-invariant approach to quantifying body composition has made strides in helping drug manufacturers retrieve better insights during their trials – particularly by enabling a shift in focus while designing trials – from simply targeting great weight reduction to achieving a high-quality weight reduction. Providing measures, such as the z-scores, that assist manufacturers in developing a more nuanced understanding of how their interventions might affect body composition beyond simple weight loss adds a new tool to allow them to differentiate their products in the fast-moving, ever-changing GLP-1 landscape of today.
We are proud and honored to be this year’s Summit Lead Partner, a testament to our commitment to doing our part in shaping the future of the obesity and weight loss drug development landscape. We can’t wait to see you there!
đź“Ą Download the full event guide here.
Interested in learning more now? Read about MRI-based muscle assessment and its use in determining the relationship between drug-induced weight reduction and muscle health here!